A5001694785- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- Ubiquitin and proteasome pathways
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Single-cell and spatial transcriptomics
- Protein Degradation and Inhibitors
- Bone and Joint Diseases
- PARP inhibition in cancer therapy
- Epigenetics and DNA Methylation
- CRISPR and Genetic Engineering
- Hematological disorders and diagnostics
- Cancer Research and Treatments
- Immune cells in cancer
- Signaling Pathways in Disease
- Phagocytosis and Immune Regulation
- Biochemical and Molecular Research
- Erythrocyte Function and Pathophysiology
- Cancer-related gene regulation
- RNA Interference and Gene Delivery
- Platelet Disorders and Treatments
The University of Texas MD Anderson Cancer Center
2022-2024
University of Perugia
2021-2022
Wellcome/MRC Cambridge Stem Cell Institute
2016-2022
Stem Cell Institute
2022
University of Cambridge
2016-2018
Medical Research Council
2016
Hematopoietic stem cells give rise to all blood in a differentiation process that involves widespread epigenome remodeling. Here we present genome-wide reference maps of the associated DNA methylation dynamics. We used meta-epigenomic approach combines profiles across many small pools and performed single-cell methylome sequencing assess cell-to-cell heterogeneity. The resulting dataset identified characteristic differences between HSCs derived from fetal liver, cord blood, bone marrow,...
Abstract Capturing where and how multipotency is lost crucial to understand blood formation controlled. Blood lineage specification currently thought occur downstream of multipotent haematopoietic stem cells (HSC). Here we show that, in human, the first restriction events within CD19 − CD34 + CD38 CD45RA CD49f CD90 (49f ) HSC compartment generate myelo-lymphoid committed with no erythroid differentiation capacity. At single-cell resolution, observe a continuous but polarised organisation 49f...
Rare hematopoietic stem and progenitor cell (HSPC) pools outside the bone marrow (BM) contribute to blood production in stress disease but remain ill-defined. Although nonmobilized peripheral (PB) is routinely sampled for clinical management, diagnosis monitoring potential of PB HSPCs untapped, as no healthy HSPC baseline has been reported. Here we comprehensively delineate human extramedullary compartments comparing spleen, PB, mobilized BM using single-cell RNA-sequencing and/or functional...
Acute myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric patients. Adoptive cell therapy by chimeric antigen receptor (CAR)-engineered T cells demonstrated a high therapeutic potential, but further development is required to ensure safe durable disease remission in AML, especially elderly To date, translation of CAR T-cell AML limited the absence ideal tumor-specific antigen. CD123 CD33 are 2 most widely overexpressed leukemic stem biomarkers their shared...
How hematopoietic stem and progenitor cell (HSPC) fate decisions are affected by genetic alterations acquired during AML leukemogenesis is poorly understood mainly explored in animal models. Here, we study isocitrate dehydrogenase (IDH) gene mutations the human model of HSPC discuss available literature on this topic. IDH1/2 occur ~20% cases, recognized among earliest leukemogenesis, targets specific inhibitors (ivosidenib enasidenib, respectively). In order to investigate direct effects...